Tenax Therapeutics Investors Alerted to Potential Class Action Lawsuit Following Substantial Losses

Tenax Therapeutics Investors Face Class Action Lawsuit

Overview

In a significant development for investors of Tenax Therapeutics, Inc. (NASDAQ: TENX), the law firm Robbins Geller Rudman & Dowd LLP has announced a class action lawsuit concerning the company's securities. Individuals who purchased or acquired Tenax stock between November 13, 2023, and August 7, 2026, have until December 28, 2026, to apply for lead plaintiff status in this case. The title of the case is Katz v. Tenax Therapeutics, Inc., and it is currently filed in the M.D.N.C court.

Allegations Against Tenax Therapeutics

The lawsuit accuses Tenax Therapeutics and several executives of breaching the Securities Exchange Act of 1934. The company focuses on developing groundbreaking cardiopulmonary therapies, and its recent press releases and investor statements have come under scrutiny. On November 13, 2023, Tenax revealed that the U.S. Food and Drug Administration had cleared their Investigational New Drug Application for their drug candidate TNX-103, intended for treating pulmonary hypertension in patients with heart failure. This announcement led to optimism among investors, resulting in significant stock purchases.

However, investors soon faced disappointment. The lawsuit claims that Tenax made a series of misleading statements regarding the efficacy of TNX-103. It is alleged that the drug was not as effective as was communicated, leading investors to believe that the clinical and commercial prospects were much more promising than the reality reflected. Consequently, the allegations state that the company's public declarations were materially misleading throughout the relevant period.

The Critical Phase 3 LEVEL Trial

In a significant setback, the company reported topline results from its Phase 3 LEVEL clinical trial on August 10, 2026. The outcomes indicated that TNX-103 failed to meet its primary endpoint regarding the improvement in walking distance compared to a placebo, raising concerns about its viability. This news dramatically affected the stock price of Tenax, which plummeted nearly 90%, impacting thousands of investors who relied on the company's optimistic assessments.

The Role of a Lead Plaintiff

The Private Securities Litigation Reform Act of 1995 allows affected investors to appoint a lead plaintiff for the class action lawsuit. This individual is expected to represent the collective interests of the class, typically acting upon the advice of their chosen law firm. The lead plaintiff's choice of legal representation plays a crucial role in the proceedings, but it is essential to note that investors' potential recoveries remain independent of their status.

About Robbins Geller Rudman & Dowd LLP

The firm representing these investors, Robbins Geller Rudman & Dowd LLP, stands as a notable authority in protecting shareholder rights and addressing securities fraud. Recently ranked #1 in the ISS Securities Class Action Services Top 50 Report, the firm has successfully recovered billions for investors, indicating its competence in handling severe investor claims. With a team of over 200 attorneys across ten offices, Robbins Geller maintains a dynamic and comprehensive approach to corporate fraud litigation.

Should investors wish to explore their options, they are encouraged to reach out through the provided resources or directly contact attorneys Ken Dolitsky or Michael Albert at Robbins Geller.

For those who have experienced substantial losses and wish to take action, the timeline is critical. The deadline for seeking appointment as lead plaintiff is fast approaching on December 28, 2026. With thorough representation and a coordinated effort, there is potential for affected investors to reclaim their losses and hold Tenax Therapeutics accountable for its alleged misrepresentations and negligence.